ThoroughCare | $5,000,000 | (Nov 20, 2024)
OneChronos | $32,000,000 | (Nov 20, 2024)
EarthOptics | $24,000,000 | (Nov 20, 2024)
Hoba Therapeutics
Denmark
- Copenhagen, Capital Region
- 12/12/2023
- Series A
- $24,800,000
Hoba Therapeutics is a Danish biotech developing restorative treatments for chronic pain disorders and hearing loss. Both indications have a clear unmet medical need for safe and efficacious treatments for millions of patients worldwide.
Hoba Therapeutics is developing HB-086 for the treatment of chronic neuropathic pain. HB-086 is a non-opioid compound with a unique mechanism of action targeting the peripheral nervous system to reverse neuropathic pain and the underlying cause of the disease.
The second drug candidate HB-097 is a pharmacological treatment for sensorineural hearing loss. Preclinical data of HB-097 show both a preventive effect of hearing loss by protecting nerve cells and a regenerative effect by reversal of already induced damage.
Hoba Therapeutics was founded in 2016 by Novo Holdings and Borean Innovation. Hoba Therapeutics received the Accelerator grant from the European Innovation Council in 2021 and the Grand Solution grant from Innovation Fund Denmark in 2018.
About chronic neuropathic pain:
Chronic neuropathic pain is a significant global health issue, affecting a substantial portion of the population worldwide. In Europe, the prevalence is estimated to be 6–8% of the general population. Chronic neuropathic pain represents an enormous personal and economic burden.
Neuropathic pain is a chronic disorder resulting from damage or dysfunction of the nervous system. Causative factors are lesions in or disorders of the nervous system, such as injury, pressure, toxic agents (e.g., chemotherapy), viral infections, and metabolic disorders. These lesions lead to aberrant functioning of sensory nerve cells, resulting in a chronic, debilitating sensation of pain.
The complexity and variability of chronic neuropathic pain necessitates a multifaceted treatment approach and highlights the need for a more effective and safer treatment options. The global neuropathic pain market is estimated to be valued at USD 7.6 bn.
- Industry Biotechnology Research
- Website https://www.hobatherapeutics.com/
- LinkedIn https://www.linkedin.com/company/hoba-therapeutics/about/
Citizen Health | $14,500,000 | (Nov 20, 2024)
Kong Inc. | $175,000,000 | (Nov 20, 2024)
RIIG | $3,000,000 | (Nov 20, 2024)
OSYTE [O-Sight] | $4,000,000 | (Nov 20, 2024)
Levanta | $20,000,000 | (Nov 20, 2024)
Jimini Health | $8,000,000 | (Nov 20, 2024)
Kalder | $10,500,000 | (Nov 20, 2024)
Lightsynq | $18,000,000 | (Nov 20, 2024)
ChapsVision | $90,000,000 | (Nov 19, 2024)